Dialysis System Articles & Analysis
-
Quanta Announces CEO Transition
Quanta Dialysis Technologies Inc (“Quanta or “The Company”), a medical technology company committed to making kidney care more accessible with its SC+ hemodialysis system, announced today that CEO John E. Milad will leave the company effective July 15, 2022. The company has begun the search for a new CEO. Upon Milad’s departure and until the appointment of a new CEO, ...
-
Photography exhibition highlights lives of people with Chronic Kidney Disease
Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”, a medical technology company committed to making kidney care more accessible with its SC+ haemodialysis system), is proud to sponsor a new photography exhibition Survivors: Life Unfiltered, running from 26 October to 7 November 2021, at the OXO Gallery in London. This exhibition was created by award winning ...
-
New survey finds that one-third of UK dialysis patients still not offered the choice of home haemodialysis despite NICE guidelines for COVID
Quanta Dialysis Technologies Ltd (“Quanta” of the “Company”, a medical technology company committed to making kidney care more accessible with its SC+ haemodialysis system, announced today the results of the UK Dialysis Patient Experience Survey, showing the wide variance in care experienced by UK dialysis patients, as well as challenges faced in assessing self-care and ...
-
Home Dialysis Patients Face Postcode Lottery of Care, New Report Finds
QUANTA Dialysis Technologies Ltd (“QUANTA” or the “Company”), a medical technology company committed to making kidney care more accessible with its SC+ haemodialysis system, has released a new report that suggests people with kidney failure who wish to do home dialysis face unequal access across the UK. The Bridging the Gap report finds that failure to offer such treatment ...
-
Bodyport Appoints John Lipman as Chief Executive Officer
Bodyport, a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions, today announced the appointment of medtech industry veteran, John Lipman, as Chief Executive Officer. Bodyport co-founder, Corey Centen, will continue as President and also serve as Chief Technology Officer (CTO) of the company. Lipman’s appointment comes as Bodyport prepares for ...
-
Canadian Ambassador to China Dominic Barton visited SWS Medical
On May 31, 2021, Mr. Dominic Barton, Canadian Ambassador to China, accompanied by Consul General Jeff David and trade commissioners from the Canadian Consulate General in Chongqing, visited SWS ...
-
Bluegrass Vascular Announces New Paper Reporting Use of the Surfacer System via Transcollateral Approach
Bluegrass Vascular Technologies, a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today the publication of a paper reporting on the use of the Surfacer® System to perform the Inside-Out® procedure via transcollateral approach. “The Surfacer Inside-out system represents a new approach to restore ...
-
Solvay Ventures invests in Invizius
Solvay Ventures announces today its equity investment in Invizius, the University of Edinburgh spin-out developing potentially lifesaving products that reduce complications rates suffered by dialysis patients. Solvay Ventures invests alongside Mercia Asset Management, Downing Ventures, the University of Edinburgh’s Old College Capital fund and the Scottish Investment Bank. Invizius is ...
-
CloudCath Announces Collaboration with American Renal Associates in Pre-Market Clinical Study for Peritoneal Dialysis Patients Innovative Remote Monitoring Platform Will Be Tested for In-Home Use
CloudCath, developer of a remote monitoring and predictive analytics platform for catheter-based treatments, today announced a collaboration with American Renal Associates (ARA), a leading provider of outpatient dialysis services. In a U.S.- based, pre-market clinical study, ARA will evaluate the use of CloudCath’s System by peritoneal dialysis (PD) patients. PD is a method of dialysis ...
By CloudCath
-
Invizius attracts £2.75m Pre-Series A investment
Invizius, the University of Edinburgh spin-out whose technology could help reduce the high death rates amongst dialysis patients, has raised £2.75m from a consortium of investors. The funding round was led by Mercia and included Downing Ventures, the University’s Old College Capital fund and the Scottish Investment Bank. The latest investment will support the company as it conducts ...
-
Invizius secures £0.5m investment
A spinout company whose technology could save the lives of thousands of dialysis patients has secured £500,000 from Mercia Asset Management, in the first investment deal since Mercia’s partnership with the University of Edinburgh was announced in November 2017. Invizius stems from years of research by Invizius co-founder, Dr Andy Herbert and his team, who believe they have ...
-
SKI Vascular Center is First Ambulatory Surgical Center in the Nation to Utilize FDA-Approved Ellipsys System for Non-Surgical Dialysis Fistula Creation
Tempe-based interventional nephrologists Randy Cooper, MD and Umar Waheed, MD, and their team at SKI Vascular Center, this week became the first ambulatory surgical center in the US to create a percutaneous arteriovenous fistula (AVF), using the Ellipsys® Vascular Access System, a game-changing innovation for patients with End-Stage Renal Disease (ESRD). The recently FDA-approved Ellipsys ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you